Voiding Dysfunction

An experimental drug that stabilizes a protein protects human bladder cells against a major UTI pathogen, researchers say.

A patient follow-up report shows promising mid-term results from five German urology centers that implemented the prostatic urethral lift (UroLift System, NeoTract, Inc.) to alleviate symptomatic BPH in patients suffering from mild, moderate, and even severe obstruction.

Laser photoselective vaporization prostatectomy using a 180W 532-nm lithium triborate laser (GreenLight XPS-180W laser system, American Medical Systems) is a safe and efficient option for treating BPH in men at high risk for surgical complications, according to findings from a large, international retrospective analysis.

Other products featured include a spacer system to protect men undergoing PCa radiotherapy, a pelvic floor exercise app, and more.

Products in the pipeline for prostate cancer, bladder cancer, stress urinary incontinence, chronic prostatitis/chronic pelvic pain syndrome, hypoactive sexual desire disorder.

Caroline Rhea and Dr. Mueller speak about the steps Doctors can take to help OAB patients, from recognizing the various symptoms and behaviors of a potential OAB patient to the treatment options available for different types of OAB.

The study shows a wide discrepancy between the least and most expensive ways to treat the common prostate condition.

The FDA has approved ceftazidime-avibactam (AVYCAZ) for two indications, including treatment of adults with complicated urinary tract infections who have limited or no alternative treatment options.

Uroplasty, Inc. announced that Cigna has written a positive coverage policy for percutaneous tibial nerve stimulation delivered via Uroplasty's Urgent PC neuromodulation system for treatment of overactive bladder and associated symptoms of urinary urgency, urinary frequency, and urge incontinence.

Despite a recent study’s promise, downsides to the procedure remain, according to one of the study’s authors.

Analyses of data from the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project are providing understanding on trends in utilization of simple prostatectomy for treatment of symptomatic BPH and addressing the gap in information about its outcomes.

The adage, “If at first you don’t succeed, try, try again,” does not appear to hold true when it comes to anticholinergic drug use in overactive bladder patients with urinary incontinence, recent study results indicate.

This article provides a real-world definition of refractory overactive bladder and its prevalence, then examines treatment options, with a focus on percutaneous tibial nerve stimulation as a noninvasive form of neuromodulation “for the masses.”

Use of the urethral lift as a treatment for BPH provided rapid improvement in symptoms, flow, and quality of life that were sustained at 2 years in a multicenter study.

More than 90% of men whose lower urinary tract symptoms (LUTS) progress do not seek treatment for their symptoms, according to recent study results that one expert cautioned against overinterpreting.

The FDA has approved ceftolozane/tazobactam (Zerbaxa) for the treatment of adults with complicated urinary tract infections.

New products and services from Samsung Electronics America, Syneron Medical, American Medical Systems, New Star, Buffalo Filter, Cook Medical, Endo International, Trimel BioPharma Metamark, and the National Comprehensive Cancer Network.

Drugs and devices in the pipeline from Actavis, Genomic Health, Lipella Pharmaceuticals, Polaris Group, Innocrin Pharmaceuticals, OncoGenex Pharmaceuticals, Heat Biologics, Repros Therapeutics, and Sophiris Bio.

Other products discussed in this article include a prosthesis for underactive bladder, a prostate cancer test, and an erectile dysfunction drug.

Repeated onabotulinumtoxinA 100 U (onabotA [Botox]) injections continue to provide benefit for patients with overactive bladder syndrome and urinary incontinence and without evidence of any new safety concerns, according to results of a pre-specified interim analysis in an open-label, 3-year extension study.

Autologous pubovaginal slings are associated with a high success rate following synthetic midurethral sling failure, according to recently published data.

The Centers for Medicare & Medicaid Services has approved two new Category I CPT codes for the UroLift system, a treatment for BPH, effective Jan. 1, 2015.

Other products featured include a 16-slice CT scanner, new generic testosterone gel, prostate cancer risk calculator, and more.

In separate actions, the FDA allowed the marketing of a urinary prosthesis for women and approved a supplemental new drug application for a lymphatic mapping agent.

Drugs and devices in the pipeline from Repros Therapeutics, Bavarian Nordic, NxThera, Solace Therapeutics, Generex Biotechnology, Bioniche, OncoCyte, HistoSonics, and Pacific Edge.